Celltrion unveils new post-hoc analyses of LIBERTY studies

South Korean biosimilars developer Celltrion (Kosdaq: 068270) late yesterday announced new post-hoc analyses of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), at the 20th European Crohn’s and Colitis Organisation (ECCO) Congress, showcasing the treatment’s effectiveness across a range of key clinical outcomes in inflammatory bowel disease (IBD).

The analyses highlight Celltrion’s ongoing efforts to evaluate the efficacy and safety of subcutaneous (SC) infliximab (CT-P13 SC) in achieving endoscopic-histologic remission in ulcerative colitis (UC), clinical and endoscopic improvement across all disease locations in Crohn’s disease (CD), supporting early clinical recapture after dose escalation following loss of response in CD and UC, and long-term drug persistence regardless of ADA in CD patients.

Celltrion developed its biosimilar Zymfentra (infliximab-dyyb), which became the first and only US Food and Drug Administration (FDA)-approved subcutaneous (SC) infliximab in November last year. The originator is Johnson & Johnson (NYSE: JNJ), which markets infliximab under the brand name Remicade.